Kisqali 400 MG daily dose 42S
Ended Awarded
- Contract number
- SPE2DB25FQRLN
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,780
Award facts
- Contract value 100% obligated
- $19,780.39 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Kisqali 400 mg daily dose tablets (42-count units) valued at $19,780.39. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded contract under open competition. The order is scheduled for completion by August 7, 2025, with performance to be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. Kisqali (ribociclib) is a targeted cancer therapy indicated for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, demonstrating the DLA's procurement of specialty pharmaceutical products to support military healthcare requirements.
This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026. As the prime contractor on this IDC, AmerisourceBergen serves as a critical pharmaceutical distributor for the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems, supplying an extensive range of brand-name and generic medications, vaccines, and medical supplies across multiple therapeutic domains. The company's extensive federal contract portfolio with the DLA demonstrates its capability to meet complex medical supply chain requirements for military and veteran healthcare systems on a global basis.
Quick answers
Who was awarded contract SPE2DB25FQRLN?
SPE2DB25FQRLN was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on August 6, 2025.
How much is contract SPE2DB25FQRLN worth?
The government has obligated $19,780 on SPE2DB25FQRLN.
Is contract SPE2DB25FQRLN an order under another contract?
Yes. SPE2DB25FQRLN is a delivery order under SPE2DB25D2207, an indefinite delivery contract.
Was contract SPE2DB25FQRLN competed?
The extent of competition for SPE2DB25FQRLN was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award